local_hospital

Azienda Ospedaliero Universitaria Careggi

Address
lock Available on a paid plan

Oncology and Solid Tumors

At Azienda Ospedaliero Universitaria Careggi, a major share of research in oncology focuses on a wide range of solid tumors, especially breast cancer, non-small cell lung cancer, colorectal cancer, gastric cancer, and renal cell carcinoma. Many studies aim to test new treatment strategies, improve outcomes after standard therapy, and better control advanced or metastatic disease.

  • Research in advanced and metastatic cancers, including lung, breast, colorectal, gastric, and kidney tumors
  • Studies in head and neck cancer, ovarian cancer, pancreatic cancer, and urothelial carcinoma
  • Trials evaluating new immunotherapy, targeted therapy, and combination treatment approaches

This activity reflects a strong focus on improving cancer control, extending survival, and refining treatment choices for patients with difficult-to-treat malignancies.

Hematology and Blood Disorders

The site also has extensive research in hematology, with trials covering acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, myelodysplastic syndromes, myelofibrosis, and other blood and lymphatic diseases. These studies are designed to test new therapies, improve disease control, and support patients whose cancers have returned or no longer respond well to standard care.

  • Studies in acute and chronic leukemias, including relapsed or high-risk disease
  • Research in lymphoma and plasma cell disorders
  • Trials focused on better symptom relief, deeper remission, and improved long-term outcomes

The breadth of this work shows a strong commitment to advancing care for both malignant and non-malignant blood disorders.

Immunology, Autoimmune, and Inflammatory Diseases

A substantial portion of research at Careggi addresses immune system diseases and chronic inflammatory conditions, including rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Crohn’s disease, ulcerative colitis, and asthma. The trials in this field often aim to reduce disease activity, improve daily symptoms, and evaluate whether newer immune-targeted treatments can offer better control than current care.

  • Research in autoimmune rheumatic diseases and connective tissue disorders
  • Studies in inflammatory bowel disease, including Crohn’s disease and ulcerative colitis
  • Trials for asthma, vasculitis, and other immune-mediated conditions

This therapeutic area highlights the site’s strong interest in treatments that modulate the immune system more precisely and safely.

Cardiology, Vascular Medicine, and Kidney-Related Research

Clinical trials at Azienda Ospedaliero Universitaria Careggi also span cardiovascular disease and kidney disease, with research in atrial fibrillation, atherosclerotic cardiovascular disease, myocardial infarction, hypertrophic cardiomyopathy, chronic kidney disease, and IgA nephropathy. These studies generally seek to improve prevention, reduce complications, and test new approaches for patients at elevated risk of heart, vessel, or renal damage.

  • Trials on stroke prevention, clotting risk, and rhythm-related heart disease
  • Studies in cardiomyopathy, acute coronary syndromes, and surgical kidney protection
  • Research in chronic kidney disease, nephropathy, and transplant-related kidney problems

The work combines treatment evaluation with efforts to better protect organ function and reduce long-term cardiovascular and renal events.

Neurology, Ophthalmology, and Rare Disease Research

The site conducts notable research in neurology, eye diseases, and rare disorders, including multiple sclerosis, migraine, Alzheimer’s disease, diabetic macular edema, age-related macular degeneration, and Fabry disease. Many of these trials aim to improve symptom control, slow disease progression, or evaluate new options for conditions with limited treatment choices.

  • Studies in demyelinating disease, headache disorders, and neurodegenerative conditions
  • Research in retinal disease, macular degeneration, and diabetic eye complications
  • Trials for inherited and uncommon disorders, including lysosomal and genetic diseases

This mix of common and rare conditions shows a broad interest in both everyday neurological care and highly specialized medicine.

Gastroenterology, Endocrine, and Other Specialized Areas

Beyond cancer and immune-mediated disease, the research portfolio includes digestive system diseases, metabolic disorders, and other specialized fields such as diabetes, liver disease, psoriatic disease, and sleep and behavioral conditions. These studies often focus on improving disease control, evaluating better supportive care, or clarifying how treatment affects day-to-day health.

  • Trials in liver, bowel, and metabolic conditions, including fatty liver disease and diabetes
  • Research in dermatologic and musculoskeletal inflammatory disorders
  • Selected studies in pain, neurological symptoms, and behavioral health-related conditions

Overall, the site supports a wide-ranging clinical research program that extends well beyond one specialty and addresses many unmet medical needs.

Site Overview

assignment
624
connected trials
corporate_fare
233
sponsors
science
649
IMPs

Activity Indicator

Last 6 months

54
Trials started
-13% vs previous period.
62
Trials started 6–12 months ago
624
Total trials linked
Highly Active
trending_downDeclining-13%
9
6
16
12
9
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 29 therapeutic areas and 15 of 649 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 624 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
319
Sponsors (total)
233
Active sponsors
167

Sponsor Network

Top 167 by active trials.

lock +166 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +86 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
624
Outperforms 99% of sites
public
Therapeutic diversity
29areas
Outperforms 98% of sites
groups
Sponsor diversity
233sponsors
Outperforms 99% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Azienda Ospedaliero Universitaria Careggi

lock Showing 1 of 624 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
"APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN".Fondazione Radioterapia Oncologica OnlusPhase IIRecruitingMar 2023

IMP list

lock Showing 1 of 649 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab54Unknown2015-11-062026-06-16

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.